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ORIGINAL ARTICLE
Chronic obstructive pulmonary disease (COPD)
is a major cause of morbidity and mortality in
adults. According to the Global Burden of Disease
Study, COPD is the fifth most common disease
and fourth leading cause of death in the world.
Both the prevalence and mortality rate are ex-
pected to increase in the coming decades.1 The
chronic course is frequently interrupted by acute
exacerbations, which contribute to most morbid-
ity and mortality of COPD patients. Bacterial in-
fections are thought to be the common etiology
of acute exacerbation. Streptococcus pneumoniae is
one of the most common bacterial species resulting
in acute exacerbation.2 In Taiwan, the incidence of
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invasive pneumococcal infection is still unknown,
but one study revealed that the overall mortality
rate of 42.5% for elderly patients (≥ 65 years old)
with invasive infection was higher than that of
22.4% for patients aged 19–64 years.3 Although
effective antimicrobial drugs have reduced case
fatality, pneumococcus remains a common global
cause of morbidity and mortality among elderly
people.4,5
In recent years, the widespread emergence of
antimicrobial resistance in S. pneumoniae has be-
come a major global concern.6,7 The Asian region
is one of the epicenters for pneumococcal resist-
ance and Taiwan has one of the highest levels of
antibiotic-resistant pneumococci in the world.7
Therefore, prevention of infection by vaccination
with pneumococcal polysaccharide is encouraged
for persons at high risk for serious pneumococcal
disease, such as the elderly and individuals with
certain underlying medical conditions such as
COPD, congestive heart failure, diabetes mellitus,
and immunocompromised patients.8
In 1911, Wright et al9 developed a crude whole-
cell pneumococcal vaccine to immunize South
African gold miners, a group with an extremely
high incidence of serious infection.10 Subsequently,
a number of other investigators conducted clini-
cal trials on the safety and efficacy of the polysac-
charide vaccines against pneumococci of various
serotypes. Although there are at least 90 known
serotypes of S. pneumoniae, the currently available
23-valent vaccine can cover more than 90% of
the serotypes that are causing invasive pneumo-
coccal infection in Taiwan.7
Good immunogenicity is essential for the 
efficacy of any vaccine. Serum antibodies to the
capsular polysaccharides are known to mediate
protection against pneumococcal infection in a
serotype-specific manner and the presence of IgG
antibody levels > 1 μg/mL have demonstrated
good correlation with significant opsonophago-
cytic activity.8 Although some studies have shown
satisfactory antibody responses to pneumococcal
vaccination in the elderly, no study from Asian
countries has assessed the antibody response in
populations with the specific disease. In the present
study, we determined the immunogenicity of 80
patients with COPD before and after pneumo-
coccal polysaccharide vaccination in Taiwan and
evaluated the outcome of these patients.
Materials and Methods
Setting and study population
Ninety-six Taiwanese patients with COPD were
sequentially enrolled at the outpatient clinics of
National Taiwan University Hospital, an 1800-bed
tertiary medical center, from 1999 to 2000. The
diagnosis of COPD was made with compatible
clinical history and symptom, risk factor, and an
irreversible component of airflow obstruction in
pulmonary function test. Of the 96 patients, 16
patients (16%) were lost to follow-up, leaving 80
patients who completed the study and were valid
subjects for analysis. To evaluate the possible dif-
ferences in antibody response with regard to age,
the 80 patients were divided into three age groups
as follows: 11 patients in the middle aged group
(50–64 years); 38 in the elderly group (65–74
years), and 31 in the advanced age group (75–93
years). None of these patients were hospitalized or
had acute illness at the time of vaccination. None
of them had received pneumococcal vaccination
prior to this study. Each patient received a single
0.5-mL subcutaneous injection of a 23-valent
pneumococcal polysaccharide vaccine (Pneumovax
23; Merck & Co., Inc., West Point, PA, USA) con-
taining 25 μg of capsular polysaccharide (CPS)
from each of the following pneumococcal types:
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Blood samples were drawn before vaccination
(80 patients), and 6 weeks (80 patients) and 52
weeks (16 patients) after vaccination. The sera were
stored frozen at −20°C until analyzed.
Methods
Specific anti-CPS IgG concentrations (μg/mL) for
the eight pneumococcal serotypes, 4, 6B, 7F, 9V,
14, 18C, 19F and 23F, in pre- and postvaccina-
tion serum samples were determined using an
enzyme-linked immunosorbent assay. All serum
samples were absorbed with cell-wall polysac-
charide to remove cross-reactive antipneumococ-
cal antibodies. Each plate included paired pre-
and postvaccination samples, positive laboratory
reference standard serum with a known concen-
tration of IgG to a specific CPS (based on the
common reference serum 89-SF), and negative
laboratory reference serum that contained no
IgG to the individual polysaccharide.
Statistical analysis
Statistical analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, IL, USA) for
Windows. An antibody fold increase was calcu-
lated by dividing the postvaccination antibody
concentration by the prevaccination antibody con-
centration. An absolute antibody rise between
the pre- and postvaccination concentrations 
(μg/mL) was obtained by subtracting the pre- from
the postvaccination levels. Differences in geomet-
ric mean concentrations (GMC) of specific IgG
between prevaccination and postvaccination sera
were calculated by the paired t test. The changes
in antibody levels (number of folds and absolute
increase) among age groups were calculated by
one-way ANOVA.
Results
Of the 80 patients who completed the study, 70
(87.5%) were male and 65 (81.25%) were smok-
ers. Table 1 shows the demographic and clinical
characteristics of the 80 patients.
Serum IgG antibody concentrations prior 
to vaccination
The proportions of the three age groups of patients
with prevaccination (baseline) and postvaccination
antibodies against the eight serotypes are shown
in Table 2. Among the different serotypes, these
COPD patients had relatively higher prevaccina-
tion antibody levels for serotypes 9, 14, 18C and
19F than for serotypes 4, 6B, 7F and 23F (Figure 1).
The percentages of low baseline antibody levels
(<1μg/mL) were the highest (81.1%) against sero-
type 4 in patients <65 years old and lowest against
serotype 14 in all three age groups (0–5.26%).
Overall, the percentage of patients’ detectable
prevaccination IgG antibody (> 1 μg/mL) ranged
from 27.5% for serotype 7F to 96.2% for serotype
14 (Figure 2). There were no significant differences
in baseline antibody concentrations against the
eight serotypes among the three age groups.
Postvaccination antibody concentrations,
fold increase, and absolute antibody rises
Among the vaccinated patients, 100% of patients
in the elderly group had antibody concentration 
> 1 μg/mL for serotypes 14 and 19, and 87–94%
for other serotypes 6 weeks after vaccination.
Elderly patients had a significant elevation in
GMCs in the serum of CPS-specific IgG to all eight
vaccine serotypes 6 weeks after immunization,
and the GMCs were not significantly different
between middle-aged and elderly adults (Table 2).
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Table 1. Demographic and clinical features of 
80 patients with chronic obstructive
pulmonary disease (COPD)
Mean age, yr (range) 72.2 (50–93)
Middle aged group (< 65), n (%) 11 (13.75)
Elderly group (65–74), n (%) 38 (47.5)
Advanced age group (≥ 75), n (%) 31 (38.75)
Male/female, n 70/10
Smoking history, n (%) 65 (81.25)
Severity of COPD, %
I (%FEV1 predicted > 80%) 14.51
II (%FEV1 predicted 50–80%) 43.55
III (%FEV1 predicted 30–50%) 30.65
IV (%FEV1 predicted < 30) 11.29
Underlying conditions, n (%)
Hypertension 8 (10)
Diabetes mellitus 10 (12.5)
Chronic renal insufficiency 9 (11.25)
Malignancy 6 (7.5)
Chronic liver disease 2 (2.5)
Old pulmonary tuberculosis 8 (10)
Chronic heart disease 7 (8.75)
Stroke 6 (7.5)
FEV1 = forced expiratory volume in 1 second.
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Figure 1. Capsular antibody titers (μg/mL) in 80 patients with chronic obstructive pulmonary disease before immunization with pneumococcal
polysaccharide vaccine. Error bars show 95% confidence interval for the geometric mean concentrations for IgG antibodies.
Table 2. Pre- and postvaccination antibody levels in 80 patients with chronic obstructive pulmonary disease*
Sero- Age 
GMC of IgG, % subjects with
Mean fold % subjects with 2-fold Absolute
type group
μg/mL (95% CI) IgG < 1 μg/mL
rise antibody rise rise
Pre Post Pre Post
4 < 65 1.11 (0.40–1.82) 8.69 (3.02–14.36) 81.81 0.00 10.88 100.00 7.58
65–74 1.51 (0.34–2.68) 10.18 (5.60–14.77) 57.89 10.53 17.99 78.94 8.67
≥ 75 1.27 (0.81–1.73) 12.22 (6.62–17.82) 51.31 3.23 15.04 87.10 10.95
6B < 65 1.42 (0.63–2.20) 12.65 (2.91–22.40) 45.45 9.09 10.06 90.91 11.23
65–74 1.87 (1.14–2.60) 33.65 (7.79–59.51) 47.37 7.89 20.45 81.58 37.78
≥ 75 1.74 (0.38–3.10) 22.31 (13.82–30.81) 48.39 3.23 24.71 93.33 20.57
7F < 65 1.01 (0.47–1.55) 24.38 (0.16–48.61) 72.73 0.00 31.29 100.00 23.38
65–74 1.26 (0.62–1.90) 12.06 (7.40–16.72) 58.42 18.42 21.74 89.47 10.80
≥ 75 1.44 (0.15–2.73) 14.42 (6.56–22.30) 64.52 6.45 21.21 86.67 12.98
9V < 65 3.49 (0.01–6.96) 33.60 (8.53–58.66) 27.27 0.00 13.50 90.91 30.11
65–74 2.73 (1.26–4.19) 21.93 (12.08–31.77) 36.64 10.53 17.43 84.21 19.20
≥ 75 2.14 (0.94–3.33) 40.95 (12.39–71.52) 32.26 6.45 21.49 96.67 38.81
14 < 65 5.51 (2.14–8.89) 50.00 (16.44–83.56) 0.00 0.00 9.36 100.00 44.49
65–74 4.97 (3.82–6.10) 35.29 (23.32–47.26) 5.26 0.00 9.35 84.21 30.32
≥ 75 6.04 (2.14–9.95) 59.29 (28.69–89.90) 3.33 0.00 16.56 80.00 52.25
18C < 65 2.94 (0.63–5.24) 22.10 (9.25–34.95) 27.27 0.00 17.55 100.00 19.16
65–74 2.71 (1.70–3.77) 20.23 (12.36–28.11) 31.58 7.89 12.16 76.32 17.52
≥ 75 2.28 (1.36–3.22) 30.89 (12.19–49.60) 40.00 3.23 24.36 90.00 28.62
19F < 65 4.09 (2.16–6.02) 52.60 (8.66–96.54) 9.09 0.00 11.15 90.91 48.51
65–74 3.54 (1.92–5.16) 38.38 (19.87–56.90) 13.16 0.00 16.95 86.84 34.84
≥ 75 2.46 (1.84–3.09) 59.13 (20.55–97.71) 13.33 0.00 35.73 86.67 56.66
23F < 65 1.66 (0.70–2.61) 24.96 (8.85–41.07) 27.27 0.00 16.88 90.91 23.30
65–74 1.84 (1.15–2.52) 15.01 (9.29–20.74) 57.89 13.16 13.53 76.32 13.18
≥ 75 2.73 (1.14–4.33) 15.90 (10.01–21.78) 36.67 3.23 11.33 63.33 13.17
*Fold increases (post/pre antibody concentration) and absolute rise (post – pre antibody concentration in mg/mL) are expressed as geometric means. GMC =
geometric mean concentration; CI = confidence interval. Differences between pre- and postvaccination GMCs in all age groups for all serotypes are statistically
significant (p<0.05, and 95% CI analysis).
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Similarly, mean fold rise and absolute increase in
CPS-specific IgG were generally comparable among
the three groups at 6 weeks after vaccination.
Because the mean fold rise may not accurately
represent differences in immune responses among
populations, we further compared the proportions
of elderly patients and younger subjects who
achieved at least a 2-fold increase in antibody
levels for the serotypes (Table 2 and Figure 2).
Compared with elderly patients, the proportion
of younger subjects with a 2-fold antibody rise was
greater for all eight serotypes. But the majority
(63.3–96.67%) of elderly patients had a 2-fold an-
tibody rise. Thus, by these criteria, at least eight
of the 23 vaccine polysaccharides appeared to be
highly immunogenic in the aged COPD patients.
Among the 16 patients with sera samples
tested for capsular IgG antibody at 52 weeks after
vaccination, a remarkable decrease in the mean
capsular IgG antibody titer was found for all eight
serotypes (Figure 3).
Discussion
Exacerbations of COPD cause morbidity, hospital
admission and mortality, and strongly influence
health-related quality of life. COPD exacerbations
have been associated with a number of etiologic
factors, including infection and pollution episodes.
The most common bacteria resulting in exacer-
bation of COPD is S. pneumoniae. In light of the
increased risk of pneumococcal disease with ad-
vancing age, and the cost associated with infection
and the rising rates of drug resistance,11 vaccination
has emerged as a public health priority.
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Figure 2. Capsular antibody responses in 80 patients with chronic obstructive pulmonary disease and at 6 weeks after
immunization with pneumococcal polysaccharide vaccine.
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Figure 3. Mean capsular IgG antibody titers (μg/mL) in 16
patients before, and 6 weeks and 52 weeks after immuni-
zation with pneumococcal polysaccharide vaccine.
Despite convincing reports in certain cohorts,
controversy still exists over the effectiveness of the
pneumococcal polysaccharide vaccine (PPV) in
older subjects. Observational studies consistently
indicated 50–70% aggregate effectiveness in pre-
venting invasive pneumococcal disease in elderly
among serotypes found in PPV.12–14 But it is
more difficult to demonstrate that PPV provided
protection against nonbacteremic pneumonia in
older persons.15,16 Because of its role in reduction
of invasive pneumococcal diseases, PPV is cost-
effective or even cost-saving.17–19 However, there
are few data available on the serotype distribu-
tion of isolates of invasive pneumococcal disease
in adults in Asia. Whether vaccination with PPV
is worthwhile depends on the burden of pneu-
mococcal disease and the cost and effectiveness
of vaccination and treatment. In Asia, these fac-
tors must be evaluated and more studies should
be done before a clear recommendation is given
for widespread use of pneumococcal vaccine in
national immunization programs.
In the present study, we measured concentra-
tions of CPS-specific IgG in baseline sera and after
immunization of adults with the 23-valent vaccine
in order to establish the effectiveness of pneumo-
coccal vaccine in Asian COPD patients. The ma-
jority of adults had appreciable levels (> 1 μg/mL)
of natural antibody to CPS prior to immuniza-
tion, presumably reflecting antibodies acquired
during life as a result of colonization or previous
infection with S. pneumoniae or cross-reacting or-
ganisms especially in patients with COPD. Besides,
several studies have suggested that elderly women
may have lower prevaccination antibody levels
to CPS and smoking seems to be associated with
higher antibody levels. In our study group, the
majority were males and almost all had a history
of smoking. Thus, the prevaccination antibody
levels in our study group may be attributable to
both sex and smoking status. Our findings re-
garding prevaccination antibody levels to CPS 
in elderly subjects are generally in agreement with
previous reports.20 We also noted that elderly adults
had similar prevaccination levels to those of a
younger cohort as has been recently reported.21–23
In the present study, the COPD patients had
relatively higher prevaccination antibody levels to
serotypes 9, 14, 18C and 19F than to serotypes 4,
6B, 7F and 23F. This may suggest that the higher-
level serotypes, especially serotype 14, were the
more prevalent isolates of pneumococcal infection
in patients with COPD. In recent studies, serotype
6B, 14, 19F and 23F were the major serotypes 
of clinical isolates of S. pneumoniae in Taiwan.7
These differences may be attributable to the 
limited size of the patient group in this study,
which focused on COPD. However, further stud-
ies on the exact serotype distribution of pneu-
mococcal infection isolates in COPD patients are
needed.
Evaluation of the change in antibody level be-
tween pre- and postvaccination in patients with
COPD in this study revealed that after vaccination,
all eight type-specific geometric mean antibody
titers were significantly higher than those before
vaccination in all subjects. Even with advanced
age (≥ 75 years), individuals seemed to retain the
ability to quantitatively respond to pneumococ-
cal vaccine. The overall percentage of elderly pa-
tients (≥ 65 years) with antibody concentrations
> 1 μg/mL to the eight antigens increased with
vaccination from 59.34% to 93.84%. The major-
ity of the subjects had 2-fold increases in specific
antibody after vaccination. This suggests that aged
Asians with COPD are capable of mounting a sig-
nificant antibody response as shown in a previous
report,24 and that COPD patients may benefit
from pneumococcal vaccination.
We analyzed the differences in antibody re-
sponses between middle-aged (50–64 years) and
elderly (≥ 65 years) patients. The anti-CPS anti-
body responses (including fold and absolute in-
crease) to the eight serotypes assayed in the elderly
or advanced-aged (> 75 years) groups were simi-
lar to those of the middle-aged group (p < 0.05).
This finding supports previous reports21,22,25 of
comparable antibody responses to CPS between
older and younger individuals.
Finally, we noted that there were significantly
different antibody responses to CPS among dif-
ferent serotypes. Serotypes 7F and 19F appeared
Pneumococcal antibody in COPD patients
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to be the most immunogenic in terms of fold rise.
In contrast, types 4, 14 and 23F, which elicited
relatively low fold increases in specific antibody,
were poorly immunogenic in our study group.
This finding is somewhat different from a previous
study,23 which found that serotype 14 seemed to
have good immunogenicity. Serotype 4 accounts
for many of the vaccine failures seen in clinical
trials and was also a leading cause of invasive pneu-
mococcal infection in several reports.25 Besides,
serotypes 23F and 19F are the most common non-
susceptible pneumococci in Taiwan.26 Although
such population-based data on pneumococcal
disease in Asian adults are lacking, our findings
suggest that the redesigning efforts of further pneu-
mococcal vaccines to improve immunogenicity
in Asian adults should pay more attention to
serotypes 4, 14 and 23F.
In this study, a significant decrease in capsular
IgG antibody to all the eight serotypes was found
1 year after vaccination, and only for serotypes
6B, 14, 19F and 23F were the levels 1 year after
vaccination higher than those before vaccination
(p < 0.05). Several previous studies showed that
antibodies to some serotypes might decline to
prevaccination levels 3–7 years after vaccination.27
Further studies to understand the chronologic
changes in capsular IgG antibody levels for these
COPD patients are needed.
There are some limitations to this study. First,
it was not a randomized control trial so we did
not have a COPD control group (nonvaccinated)
to better evaluate the efficacy. Second, although all
the patients had prevaccination and 6-week sero-
logic determination, only 16 patients had follow-
up serologic data at 52 weeks after vaccination.
Third, avidity of the induced antibodies is impor-
tant and this was not investigated in this study.
In summary, Taiwanese elderly adults with
COPD, even in advanced age, can mount a 
significant antibody response to pneumococcal
polysaccharide vaccine, according to our results.
Therefore, our results may support the existing
recommendation that pneumococcal vaccine be
offered to everyone with chronic lung disease
who are ≥ 65 years old.
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